Enfusion (ENFN)
(Delayed Data from NYSE)
$9.73 USD
-0.05 (-0.51%)
Updated May 7, 2024 04:00 PM ET
After-Market: $9.74 +0.01 (0.10%) 7:58 PM ET
4-Sell of 5 4
F Value A Growth C Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ENFN 9.73 -0.05(-0.51%)
Will ENFN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ENFN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ENFN
Radware (RDWR) Surpasses Q1 Earnings and Revenue Estimates
Enfusion, Inc. (ENFN) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
ENFN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Enfusion, Inc. (ENFN) Lags Q4 Earnings Estimates
Box (BOX) Q4 Earnings Beat Estimates
Strength Seen in Phunware (PHUN): Can Its 75.3% Jump Turn into More Strength?
Other News for ENFN
ENFN Crosses Above Average Analyst Target
Notable Two Hundred Day Moving Average Cross - ENFN
Enfusion Announces Date of First Quarter 2024 Results
Piper Sandler Reaffirms Their Hold Rating on Enfusion (ENFN)
The 3 Most Undervalued Under-$10 Stocks to Buy in April 2024